Masimo (NSDQ:MASI) announced that it successfully completed the previously announced acquisition of Lidco for $40.1 million.
Irvine, Calif.-based Masimo acquired 100% of Lidco, a provider of advanced hemodynamic monitoring solutions, on Feb. 2, 2021. Lidco was de-listed from the AIM submarket of the London Stock Exchange on Jan. 11 and will be re-registered by Masimo as a UK-based private subsidiary, according to a news release.
Masimo and Lidco confirmed in a November announcement that they agreed on the terms of a recommended cash offer to be made by Masimo for the entire issued and to be issued share capital of Lidco, totaling the $40.1 million (£31.1 million) as shares are valued at about 15¢ (£0.12) per share.With a market capitalization of about $12 billion, according to the November announcement, Masimo is acquiring in Lidco a hemodynamic monitoring device maker that targets critical care and high-risk surgical patients with primary markets in the U.S. …